Current oncology最新文献

筛选
英文 中文
Cancer Cachexia and the Heart: A Review with Focus on China. 癌症恶病质与心脏:以中国为中心的研究综述。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-20 DOI: 10.3390/curroncol33100635
Siqi Wang, Zihao Chen, Jochen Springer
{"title":"Cancer Cachexia and the Heart: A Review with Focus on China.","authors":"Siqi Wang, Zihao Chen, Jochen Springer","doi":"10.3390/curroncol33100635","DOIUrl":"10.3390/curroncol33100635","url":null,"abstract":"<p><p>Cancer cachexia is a systemic, multifactorial syndrome characterized by progressive depletion of skeletal muscle, disruption of metabolic homeostasis, and reduced survival. In experimental models, cachexia-associated mediators, including inflammatory cytokines, myostatin-related signaling, and proteolytic activation, have been implicated in driving cardiac atrophy, interstitial fibrosis, and impaired myocardial function. Conversely, data from chronic heart failure suggest that reduced tissue perfusion, neurohormonal activation, and sustained inflammation secondary to cardiac dysfunction may further aggravate skeletal muscle wasting. These observations suggest a bidirectional relationship between cancer cachexia and cardiac dysfunction, which has not been tested in patients with cancer. Approximately 4.82 million new cancer cases occur in China annually, with a disease distribution predominated by gastrointestinal, hepatobiliary, and thoracic malignancies, all of which carry high risks of cachexia. Among 710,170 Chinese patients with cancer, 5.0% had cardiovascular disease and 13.0% had at least one cardiovascular risk factor. These figures indicate a large population at risk, but they do not show that cardiac involvement in Chinese patients differs in frequency, phenotype, or clinical impact from that in other populations; to our knowledge, no prospective data on cancer-associated cardiac involvement have been reported for Chinese patients, and cachexia assessment does not include cardiac biomarkers or echocardiographic measures. This review summarizes cancer cachexia epidemiology in China, shows the evidence linking cachexia to cardiac wasting, and evaluates how cardiac dysfunction may in turn influence the cachectic trajectory. Accordingly, we outline the key clinical and mechanistic questions that remain unanswered in Chinese patients and propose a research agenda in which cardiac assessment is evaluated prospectively before it is considered for routine care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors. 八十多岁乳腺癌患者的癌症特异性生存率:预后因素的竞争风险分析。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-20 DOI: 10.3390/curroncol33100636
Özlem Mermut, Berrin Yalçın, Rıza Umar Gürsu, Esra Arslan, Bülent Akçe, Didem Can Trabulus, Semiha Battal Havare, Serap Karabıyık
{"title":"Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors.","authors":"Özlem Mermut, Berrin Yalçın, Rıza Umar Gürsu, Esra Arslan, Bülent Akçe, Didem Can Trabulus, Semiha Battal Havare, Serap Karabıyık","doi":"10.3390/curroncol33100636","DOIUrl":"10.3390/curroncol33100636","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated long-term survival outcomes in breast cancer patients aged ≥80 years, focusing on how prognostic factors change when competing mortality risks are considered.</p><p><strong>Methods: </strong>We retrospectively analyzed 106 octogenarian breast cancer patients treated between 2013 and 2023. Endocrine therapy was evaluated as a treatment-related prognostic factor. Treatment-related prognostic factors were evaluated using multivariable Cox proportional hazards and Fine-Gray competing-risks models.</p><p><strong>Results: </strong>The median age was 82 years, and the median follow-up time was 27.5 months (range, 6-99 months). In the multivariable Cox proportional hazards, biopsy compared with surgery (HR, 0.56; <i>p</i> = 0.037), presence of endocrine therapy (HR, 0.38; <i>p</i> = 0.003), and CCI ≥ 8 (HR, 9.96; <i>p</i> < 0.001) were independently associated with OS. In the Fine-Gray model, the associations of surgical procedure (<i>p</i> = 0.120) and endocrine therapy (<i>p</i> = 0.081) with breast cancer-specific mortality were no longer statistically significant. CCI ≥ 8 remained significantly associated with breast cancer-specific mortality (sHR, 3.76; 95% CI, 1.52-9.31; <i>p</i> = 0.004).</p><p><strong>Conclusions: </strong>In octogenarian breast cancer patients, surgery and endocrine therapy were associated with improved OS, but their associations with breast cancer-specific mortality were attenuated after accounting for competing risks. High CCI emerged as the most robust prognostic factor. These findings support incorporating comorbidity burden and competing-risks assessment into individualized treatment decisions in this population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial. 电针联合认知行为疗法治疗失眠可减轻妇科癌症化疗患者的失眠-焦虑共病:一项随机对照试验
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-19 DOI: 10.3390/curroncol33100628
Ting Xu, Yanqiu Rao, Qi Cao, Yalin Yue
{"title":"Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.","authors":"Ting Xu, Yanqiu Rao, Qi Cao, Yalin Yue","doi":"10.3390/curroncol33100628","DOIUrl":"10.3390/curroncol33100628","url":null,"abstract":"<p><p>Insomnia and anxiety affect many gynecological cancer patients on chemotherapy, and non-pharmacological options are limited. This randomized trial examined whether adding electroacupuncture (EA) to cognitive behavioral therapy for insomnia (CBT-I) improves both conditions. Seventy-six patients received EA + CBT-I or sham EA + CBT-I for 4 weeks. Outcomes included sleep quality (PSQI), insomnia severity (AIS), anxiety (HAMA), objective sleep parameters, and overall response rate. At Week 4, the EA group showed a greater reduction in PSQI global score (mean difference in change from baseline: -3.11, 95% CI: -4.11 to -2.11, <i>p</i> < 0.001). More patients in the EA group achieved AIS ≤ 6 (71.1% vs. 42.1%, <i>p</i> = 0.010) and HAMA ≤ 14 (92.1% vs. 65.8%, <i>p</i> = 0.005). Deep sleep (<i>p</i> = 0.001), REM sleep (<i>p</i> = 0.045), and sleep score (<i>p</i> = 0.008) also increased more with EA group. The overall response rate was higher with EA (92.1% vs. 71.1%, <i>p</i> = 0.016). No serious adverse events occurred. These findings suggest that adding EA to CBT-I improves sleep and anxiety in this population, with a favorable safety profile.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer. 2025年加拿大全国胰腺会议:以患者为中心的胰腺癌管理的最新进展。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-19 DOI: 10.3390/curroncol33100629
Jessica L Nickerson, Stefanie Condon-Oldreive, Erica Tsang, George Zogopoulos, Rodney Ouellette, Orçun Haçariz, Beatriz Antón Pascual, Pablo E Serrano, Sharlene Gill, Saman Maleki Vareki, Louise Binder, Leah Stephenson, Breffni Hannon, Jaymee Maaghop, Popi Kasvis, Ken Leslie
{"title":"Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer.","authors":"Jessica L Nickerson, Stefanie Condon-Oldreive, Erica Tsang, George Zogopoulos, Rodney Ouellette, Orçun Haçariz, Beatriz Antón Pascual, Pablo E Serrano, Sharlene Gill, Saman Maleki Vareki, Louise Binder, Leah Stephenson, Breffni Hannon, Jaymee Maaghop, Popi Kasvis, Ken Leslie","doi":"10.3390/curroncol33100629","DOIUrl":"10.3390/curroncol33100629","url":null,"abstract":"<p><p>Pancreatic cancer (PC) is among the most lethal malignancies with slower progress in overall survival and treatment options compared to other cancers. The 2025 Canadian National Pancreas Conference (NPC)-the third biennial event of its kind-was hosted by Craig's Cause Pancreatic Cancer Society and the Baker Centre for Pancreatic Cancer in November 2025 in London, Ontario, co-organized by the Canadian Association of General Surgeons (CAGS) with accreditation through the Royal College of Physicians and Surgeons of Canada. The event brought together experts across healthcare disciplines as well as researchers, students, and allied professionals to discuss the latest advances in treatment and management of this complex disease. The conference featured presentations, workshops, and discussions on the current landscape of treatment and management of PC with an emphasis on the increasing significance of genomic sequencing, equitable care, and a multidisciplinary approach.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear Eccentricity as a Potential Biomarker for Tumor Biology and Survival in Glioblastoma. 核偏心率作为胶质母细胞瘤肿瘤生物学和生存的潜在生物标志物。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-17 DOI: 10.3390/curroncol33100627
Luna Han, Teresia John, Mohid Hassan, Jonathan J Wisco
{"title":"Nuclear Eccentricity as a Potential Biomarker for Tumor Biology and Survival in Glioblastoma.","authors":"Luna Han, Teresia John, Mohid Hassan, Jonathan J Wisco","doi":"10.3390/curroncol33100627","DOIUrl":"10.3390/curroncol33100627","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate whether quantitative nuclear morphology from routine H&E images can be used as a biomarker for glioblastoma (GBM) biology and prognosis. <b>Methods:</b> Nuclear eccentricity, circularity, density, and heterogeneity were measured from H&E whole-slide images in the TCGA-GBM cohort and independently validated in the CPTAC-GBM cohort. A multivariable Cox model was used to test the survival associations in both cohorts, and transcriptome-wide and gene set enrichment analyses were conducted in TCGA RNA data and validated using CPTAC RNA and proteomic data. <b>Results:</b> In TCGA-GBM, greater nuclear eccentricity was associated with better survival (HR, 0.85; 95% CI, 0.71-1.02; <i>p</i> = 0.089), with the same favorable association independently observed in CPTAC-GBM (HR, 0.74; 95% CI, 0.60-0.90; <i>p</i> = 0.003). No individual gene association with eccentricity was statistically significant in the TCGA cohort, but pathway analysis identified its association with epithelial-mesenchymal transition (EMT), inflammatory, hypoxic, and stress-related programs. Across the TCGA RNA, CPTAC RNA and proteomic datasets, greater eccentricity was consistently associated with increased NF-κB signaling, collagen biosynthesis, and ER-to-Golgi transport and decreased L1CAM-related and neuronal-projection programs, with EMT showing the strongest cross-cohort consistency. <b>Conclusions:</b> Nuclear eccentricity from patient H&E slide images is a potential biomarker associated with survival and transcriptional/translational programs in GBM. Integrating quantitative pathology with RNA and proteomic data may provide an accessible approach for GBM prognosis and tumor biology characterization.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation. 基于mri的放射组学模型预处理预测宫颈神经内分泌癌病理性淋巴结转移:双中心发展和外部验证。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-16 DOI: 10.3390/curroncol33100625
Jian Chen, Fengle Jiang, Xingfa Chen, Rong Lin, Ning Ma, Haijuan Yu, Yang Sun
{"title":"MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation.","authors":"Jian Chen, Fengle Jiang, Xingfa Chen, Rong Lin, Ning Ma, Haijuan Yu, Yang Sun","doi":"10.3390/curroncol33100625","DOIUrl":"10.3390/curroncol33100625","url":null,"abstract":"<p><p><b>Objectives:</b> To develop and externally validate MRI-based radiomics and clinicoradiomics models for predicting pathological lymph node metastasis (LNM) in neuroendocrine carcinoma of the cervix (NECC). <b>Methods:</b> This retrospective two-center study included 133 patients who underwent pretreatment pelvic MRI and pathological nodal assessment: 93 for development and 40 for external validation. Intratumoral and peritumoral features were extracted from T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted images. Stratified nested fivefold cross-validation evaluated the complete revised selection process. Locked models were assessed for discrimination, calibration, and exploratory net benefit, with conventional MRI nodal assessment as a comparator. <b>Results:</b> Pathological LNM was present in 54/133 patients (40.6%). The selected radiomics-only k-nearest neighbors (KNN) model had an external AUC of 0.783 (95% CI, 0.630 to 0.935), accuracy of 0.800, sensitivity of 0.813, and specificity of 0.792. The complete selection procedure yielded an out-of-fold AUC of 0.731. External AUCs were 0.727 for the clinical/MRI model and 0.767 for the clinicoradiomics model; neither fusion model differed significantly from the clinical/MRI comparator. Conventional MRI sensitivity was 0.563, with no significant paired difference from the selected model (<i>p</i> = 0.125). External calibration was imperfect (Brier score, 0.186; slope, 0.672). <b>Conclusions:</b> MRI radiomics showed moderate external discrimination of pathological LNM in NECC. Adding clinical variables did not demonstrate further benefit. Multicenter validation, recalibration, and clinical-impact assessment are needed before clinical application.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series. 晚期实体恶性肿瘤肝移植受者的免疫治疗:3例病例系列。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-16 DOI: 10.3390/curroncol33100623
Belinda Jiao, Charles Vincent Rajadurai, Nissim Benizri, Arielle Sabbah, Scott Owen, Khashayar Esfahani, Marc Deschenes, Philip Wong, Xun Zhao, Jamil Asselah
{"title":"Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series.","authors":"Belinda Jiao, Charles Vincent Rajadurai, Nissim Benizri, Arielle Sabbah, Scott Owen, Khashayar Esfahani, Marc Deschenes, Philip Wong, Xun Zhao, Jamil Asselah","doi":"10.3390/curroncol33100623","DOIUrl":"10.3390/curroncol33100623","url":null,"abstract":"<p><p>The use of immune checkpoint inhibitors (ICIs) after liver transplantation (LT) remains controversial, because immune activation may cause allograft rejection. Evidence in non-hepatocellular carcinoma (HCC) malignancies is limited. We retrospectively reviewed three LT recipients treated with pembrolizumab for advanced non-HCC malignancies at the McGill University Health Centre; treatment began between May 2020 and January 2025, and follow-up was censored on 31 January 2026. A patient with PD-L1-negative non-small cell lung cancer (NSCLC) achieved stable disease for approximately seven months, whereas a patient with PD-L1-high NSCLC achieved a durable partial response with progression-free survival of approximately 36 months. A third patient with cutaneous squamous cell carcinoma achieved a near-complete radiologic and metabolic response after two cycles. Pembrolizumab was held after this response; subsequent liver-test abnormalities raised concern for graft injury, but biopsy showed no histologic rejection and supported treatment resumption. No clinical or biochemical evidence of rejection was observed in Cases 1 and 2. At cutoff, Case 3 was alive and receiving pembrolizumab after seven cycles. These cases support a cancer-specific, individualized risk-benefit assessment in which expected oncologic benefit, alternatives, graft history, immunosuppression, and acceptance of graft-loss risk guide multidisciplinary treatment and close graft surveillance.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline AI Economic Literacy and Enacted Adoption of Artificial Intelligence Tools by Oncology and Critical Care Professionals. 基线人工智能经济素养和肿瘤和重症监护专业人员实施人工智能工具的采用。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-16 DOI: 10.3390/curroncol33100626
Dragoș-Ciprian Negoiță, Ciprian Gindac, Akhil Akula, Karina Cristina Marin, Adrian Cosmin Ilie
{"title":"Baseline AI Economic Literacy and Enacted Adoption of Artificial Intelligence Tools by Oncology and Critical Care Professionals.","authors":"Dragoș-Ciprian Negoiță, Ciprian Gindac, Akhil Akula, Karina Cristina Marin, Adrian Cosmin Ilie","doi":"10.3390/curroncol33100626","DOIUrl":"10.3390/curroncol33100626","url":null,"abstract":"<p><p>We examined whether baseline artificial intelligence (AI) economic literacy was associated with sustained use of oncology AI tools. This prospective cohort included 96 oncology and critical care professionals at two centres in Timișoara, Romania, followed for 12 months after institutional roll-out. Participants were classified by AI Economic Literacy Index (AIELI) scores as high (≥14) or low (<14). Sustained use required log-verified activity in at least two of the final three months. Analyses included regression, inverse probability of treatment weighting and exploratory indirect-association analysis through return-on-investment (ROI) confidence. Among 91 completers, sustained use occurred in 29/53 high-literacy participants (54.7%) and 7/38 low-literacy participants (18.4%; risk ratio 2.97, 95% confidence interval 1.46-6.06). The weighted risk ratio was 2.24 (1.15-4.34), and the profession-stratified risk ratio was 2.80 (1.36-5.76). Median time to first use was 5.8 months in the high-literacy group and was not reached in the low-literacy group. Nine participants (eight high-literacy, one low-literacy) had recorded use before the baseline assessment; in a delayed-entry analysis restricted to the 87 participants unused at assessment, the crude hazard ratio for subsequent first use was 2.98 (1.62-5.48) and the crude risk ratio for sustained use after excluding prior users was 3.01 (1.36-6.64); the corresponding covariate-adjusted estimates were less precise (hazard ratio 1.81, 0.89-3.69; risk ratio 2.19, 0.99-4.86) and their confidence intervals included the null. Roll-out-based time-to-first-use comparisons are descriptive because they include events preceding measurement. Sustained use increased across literacy bands. An indirect association through ROI confidence was observed but was not interpretable as causal mediation. Higher baseline economic literacy was associated with earlier and more sustained recorded AI-tool use, although opportunity for use differed by profession, and the adjusted timing-corrected estimates leave the independent contribution of literacy uncertain. Larger multicentre studies should evaluate whether literacy training improves adoption and whether adoption translates into clinical or economic benefit.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing. [177Lu]Lu-PSMA-617在转移性激素敏感前列腺癌中的作用:psmadd的证据和治疗序列的考虑。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-16 DOI: 10.3390/curroncol33100624
Carlo Buonerba, Giuseppe Di Lorenzo
{"title":"[<sup>177</sup>Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.","authors":"Carlo Buonerba, Giuseppe Di Lorenzo","doi":"10.3390/curroncol33100624","DOIUrl":"10.3390/curroncol33100624","url":null,"abstract":"<p><p>Introducing [<sup>177</sup>Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narrative review examines PSMAddition alongside evidence on alternative treatments, prostate-specific membrane antigen (PSMA) imaging, safety, and subsequent therapy. In the peer-reviewed analysis, with a data cutoff of 13 January 2025, adding radioligand therapy to androgen-deprivation therapy and an investigator-selected androgen receptor pathway inhibitor improved radiographic progression-free survival (hazard ratio 0.72; 95% confidence interval 0.58-0.90). Overall survival was immature and did not meet the prespecified interim significance threshold (hazard ratio 0.84; 95% confidence interval 0.63-1.13). A subsequent non-peer-reviewed sponsor update supported the radiographic findings, although the updated analysis was not controlled for type I error and overall survival remained immature. Radioligand intensification increased grade ≥3 adverse events (51% versus 43%). Prespecified composite quality-of-life and pain endpoints showed no statistically significant differences, although their interpretation is limited by the inclusion of progression or death. Control-arm crossover after progression was optional. Direct mHSPC evidence is distinguished from contextual castration-resistant evidence. Neither a preferred hormonal partner nor superiority over docetaxel-containing triplet therapy has been established. A non-prescriptive five-domain framework integrates target expression, disease characteristics, patient fitness, subsequent treatment options, and delivery capacity to support multidisciplinary assessment.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies. 铂耐药卵巢癌治疗测序的新时代:整合免疫治疗、抗体-药物偶联物和靶向治疗。
IF 3.6 4区 医学
Current oncology Pub Date : 2026-10-15 DOI: 10.3390/curroncol33100622
Seiji Mabuchi, Ai Kusakabe, Yumi Takimoto
{"title":"A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.","authors":"Seiji Mabuchi, Ai Kusakabe, Yumi Takimoto","doi":"10.3390/curroncol33100622","DOIUrl":"10.3390/curroncol33100622","url":null,"abstract":"<p><p>Platinum-resistant ovarian cancer (PROC) has historically been treated with sequential non-platinum chemotherapy, with bevacizumab added when appropriate. The therapeutic landscape has expanded with positive randomized phase III data for pembrolizumab plus weekly paclitaxel with or without bevacizumab (KEYNOTE-B96), mirvetuximab soravtansine (MIRV) in FRα-high disease (MIRASOL), and relacorilant plus nab-paclitaxel (ROSELLA). Trastuzumab deruxtecan (T-DXd) has also shown substantial activity in previously treated HER2-expressing ovarian cancer, although its ovarian cohort was small, nonrandomized, and not restricted to PROC. These trials enrolled different populations and do not establish a cross-trial efficacy hierarchy. We therefore review the development of immunotherapy leading to KEYNOTE-B96, compare newer strategies with established PROC treatments, distinguish phase III evidence from regulatory approval and routine availability, and propose an evidence-informed framework for treatment selection and sequencing. The framework prioritizes current treatment opportunity while accounting for biomarker eligibility, prior treatment, residual toxicity, treatment and financial burden, patient priorities, and the feasibility of later-line therapy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书